Recently, the National Health Insurance Administration and the Ministry of Human Resources and Social Security issued the “Catalogue of Drugs for National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance” and the first edition of the “Catalogue of Innovative Drugs for Commercial Health Insurance”. The first edition of the new medical insurance “Double Catalogue” of commercial insurance will be officially implemented nationwide on January 1, 2026. From December 7 to 8, many listed companies, including Hengrui Pharmaceuticals, Fosun Pharmaceuticals, Hisilco, Beihai Kangcheng, and Junshi Biotech, announced the inclusion of new drugs, renewals, or additional indications in the new edition of the National Health Insurance Catalogue and the first edition of the Commercial Insurance Innovative Drug Catalogue.

Zhitongcaijing · 1d ago
Recently, the National Health Insurance Administration and the Ministry of Human Resources and Social Security issued the “Catalogue of Drugs for National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance” and the first edition of the “Catalogue of Innovative Drugs for Commercial Health Insurance”. The first edition of the new medical insurance “Double Catalogue” of commercial insurance will be officially implemented nationwide on January 1, 2026. From December 7 to 8, many listed companies, including Hengrui Pharmaceuticals, Fosun Pharmaceuticals, Hisilco, Beihai Kangcheng, and Junshi Biotech, announced the inclusion of new drugs, renewals, or additional indications in the new edition of the National Health Insurance Catalogue and the first edition of the Commercial Insurance Innovative Drug Catalogue.